Company Profile
Lineage Cell Therapeutics Stock Price, News & Catalysts
- Ticker:
- LCTX
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.03 USD (-3.74%)
Close
Last updated: September 17, 2026
302M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, LCTX closed down 3.74% at $1.03. No new same-company headline was identified in the current news window.
Company overview
Pluripotent Cell Therapy Company
Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
OpRegen
RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy.
Wholly Owned Pipeline
Lineage is applying its platform to oligodendrocyte, auditory neuron, and corneal endothelial cell programs, including the newly launched COR1 program.
Manufacturing Model
The company differentiates and expands specific cell types from pluripotent master cell banks, supporting consistent and scalable production.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics (LCTX) most recently closed at 1.03 USD, a -3.74% move versus the previous session.
What is the market cap of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics currently has a market capitalization of 302M USD on BioPharmSignal.
What does Lineage Cell Therapeutics do?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy. Wholly Owned...
On which exchange is LCTX stock listed?
Lineage Cell Therapeutics (LCTX) is associated with AMEX, United States, Biopharma.
What is Pluripotent?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
Which conditions is Lineage Cell Therapeutics targeting with Pluripotent?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy. Wholly Owned...
What is Cell?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
What is Therapy?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.